Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC1102 + nucleos(t)ide analogues
- Development stage
- Unknown
- Lead developer
- GC Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
GC1102 + nucleos(t)ide analogues is a **combination therapy** under investigation for the treatment of **chronic hepatitis B virus (HBV) infection**. GC1102 (also known as lenvervimab) is a recombinant human monoclonal antibody targeting the **hepatitis B surface antigen (HBsAg)**, functioning both as a neutralizer of circulating HBV particles and as an immunostimulant by enhancing immune-mediated clearance. Nucleos(t)ide analogues (NAs) are a class of small-molecule antiviral agents that inhibit the HBV polymerase, thereby blocking viral DNA synthesis and suppressing HBV replication. The combination aims to increase the chance of functional cure by reducing HBsAg titers and controlling HBV replication, targeting different stages of the viral life cycle. Clinical studies have shown that combining GC1102 with NAs results in more robust reductions of HBsAg than NAs alone, potentially increasing rates of sustained virologic response and functional cure in HBV patients.
- Brand names
- Hepabig Gene
- Other names
- lenvervimabrecombinant hepatitis B human immunoglobulin
02
Targets
HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on GC1102 + nucleos(t)ide analogues.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC1102 + nucleos(t)ide analogues.